Payment overview · 2025
General Payments
$566.72
29 reported records · 10 companies
Healthcare provider profile · identity verified
Dwight Marshall Williams, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · PARAGOULD, AR · NPI 1619930591
Verified facts
What the public records show
CMS Open Payments records show Dwight Marshall Williams, M.D. received $566.72 in general payments during 2025 across 29 reported records.
AstraZeneca Pharmaceuticals LP accounted for 27.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Paxlovid, Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 190 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tresiba as an associated drug or biological on 415 records involving 264 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Tresiba by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 323 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $155.57 | 27.4% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $134.72 | 23.8% | 12 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $95.54 | 16.9% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $62.40 | 11.0% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $28.36 | 5.0% | 2 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $24.37 | 4.3% | 1 | 2025 |
| Tris Pharma Inc | Unresolved — no canonical attribution shown | $17.30 | 3.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.15 | 3.0% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $16.12 | 2.8% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.19 | 2.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $566.72 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $155.57 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $141.87 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $141.87 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $95.54 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $80.19 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $67.27 | 7 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $48.68 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $48.56 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $48.56 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $28.36 | 2 | 2025 |
Source payment records
|
|||||
| FABRAZYME Normalized: fabrazyme |
Biological | GENZYME CORPORATION | $24.37 | 1 | 2025 |
Source payment records
|
|||||
| Dyanavel XR Normalized: dyanavel xr |
Drug | Tris Pharma Inc | $17.30 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $17.15 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $16.12 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.19 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.66 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $13.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 190 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 67 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 21 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
190 | 19 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
62 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
67 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Tresiba open payments reported associated product |
CMS Open Payments — General Payments 415 supporting records · 264 recipient NPIs · example record 1188130328 |
Tresiba · 2024 Exact normalized brand match · 1 Part D row |
65 | 11 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
323 | 39 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
21 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Furosemide | Furosemide | 940 | 108 |
| Levothyroxine Sodium | Levothyroxine Sodium | 817 | 98 |
| Amlodipine Besylate | Amlodipine Besylate | 725 | 113 |
| Potassium Chloride | Potassium Chloride | 612 | 79 |
| Pantoprazole Sodium | Pantoprazole Sodium | 520 | 93 |
| Atorvastatin Calcium | Atorvastatin Calcium | 484 | 110 |
| Lisinopril | Lisinopril | 476 | 94 |
| Dexlansoprazole Dr | Dexlansoprazole | 421 | 25 |
| Tramadol Hcl | Tramadol Hcl | 389 | 79 |
| Losartan Potassium | Losartan Potassium | 380 | 74 |
| Gabapentin | Gabapentin | 368 | 69 |
| Clopidogrel | Clopidogrel Bisulfate | 340 | 63 |
| Escitalopram Oxalate | Escitalopram Oxalate | 339 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 334 | 64 |
| Eliquis | Apixaban | 323 | 39 |
| Metformin Hcl | Metformin Hcl | 318 | 71 |
| Alprazolam | Alprazolam | 293 | 52 |
| Metoprolol Tartrate | Metoprolol Tartrate | 274 | 48 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 239 | 47 |
| Pravastatin Sodium | Pravastatin Sodium | 232 | 48 |
| Omeprazole | Omeprazole | 222 | 53 |
| Hydrochlorothiazide | Hydrochlorothiazide | 212 | 42 |
| Carvedilol | Carvedilol | 202 | 37 |
| Simvastatin | Simvastatin | 198 | 46 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 196 | 39 |
| Citalopram Hbr | Citalopram Hydrobromide | 191 | 32 |
| Farxiga | Dapagliflozin Propanediol | 190 | 19 |
| Metoprolol Succinate | Metoprolol Succinate | 188 | 36 |
| Quetiapine Fumarate | Quetiapine Fumarate | 186 | 25 |
| Xarelto | Rivaroxaban | 183 | 16 |
| Sertraline Hcl | Sertraline Hcl | 181 | 29 |
| Meloxicam | Meloxicam | 179 | 42 |
| Donepezil Hcl | Donepezil Hcl | 176 | 24 |
| Diazepam | Diazepam | 158 | 26 |
| Allopurinol | Allopurinol | 154 | 31 |
| Famotidine | Famotidine | 147 | 23 |
| Trazodone Hcl | Trazodone Hcl | 140 | 23 |
| Sucralfate | Sucralfate | 137 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 134 | 31 |
| Lorazepam | Lorazepam | 133 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 128 | 37 |
| Celecoxib | Celecoxib | 119 | 23 |
| Levetiracetam | Levetiracetam | 117 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 117 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 115 | 21 |
| Atenolol | Atenolol | 113 | 28 |
| Divalproex Sodium | Divalproex Sodium | 113 | 16 |
| Glipizide | Glipizide | 113 | 24 |
| Memantine Hcl | Memantine Hcl | 113 | 23 |
| Mirtazapine | Mirtazapine | 110 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 104 | 19 |
| Amiodarone Hcl | Amiodarone Hcl | 103 | 15 |
| Buspirone Hcl | Buspirone Hcl | 103 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 103 | 19 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 103 | 23 |
| Megestrol Acetate | Megestrol Acetate | 103 | 32 |
| Ondansetron Hcl | Ondansetron Hcl | 101 | 29 |
| Clonazepam | Clonazepam | 100 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 100 | 21 |
| Clonidine Hcl | Clonidine Hcl | 99 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 97 | 21 |
| Prednisone | Prednisone | 96 | 39 |
| Finasteride | Finasteride | 90 | 22 |
| Januvia | Sitagliptin Phosphate | 89 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 89 | 30 |
| Cefdinir | Cefdinir | 83 | 72 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 82 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 78 | 14 |
| Entresto | Sacubitril/Valsartan | 77 | suppressed |
| Metolazone | Metolazone | 77 | 13 |
| Ondansetron Odt | Ondansetron | 77 | 27 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 76 | 19 |
| Montelukast Sodium | Montelukast Sodium | 74 | 11 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 72 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 71 | 13 |
| Ezetimibe | Ezetimibe | 70 | suppressed |
| Azithromycin | Azithromycin | 68 | 62 |
| Ozempic | Semaglutide | 67 | 13 |
| Bupropion Xl | Bupropion Hcl | 66 | 13 |
| Dilt-Xr | Diltiazem Hcl | 66 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 66 | 15 |
| Candesartan Cilexetil | Candesartan Cilexetil | 65 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 65 | suppressed |
| Tresiba | Insulin Degludec | 65 | 11 |
| Fiasp | Insulin Aspart (Niacinamide) | 62 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 59 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 59 | 14 |
| Memantine Hcl Er | Memantine Hcl | 58 | suppressed |
| Aripiprazole | Aripiprazole | 57 | 11 |
| Myrbetriq | Mirabegron | 56 | suppressed |
| Pregabalin | Pregabalin | 56 | suppressed |
| Spironolactone | Spironolactone | 56 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 55 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 53 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 52 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 52 | 12 |
| Lovastatin | Lovastatin | 51 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 51 | 42 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 50 | suppressed |
| Unifine Safecontrol Pen Needle | Pen Needle,dual Safety,diabetc | 50 | 12 |
| Warfarin Sodium | Warfarin Sodium | 50 | suppressed |
| Ibuprofen | Ibuprofen | 48 | 14 |
| Metformin Hcl Er | Metformin Hcl | 47 | 13 |
| Morphine Sulfate Er | Morphine Sulfate | 47 | suppressed |
| Primidone | Primidone | 47 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 46 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 45 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 45 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 44 | suppressed |
| Fluconazole | Fluconazole | 43 | 27 |
| Jardiance | Empagliflozin | 43 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 42 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 42 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 42 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 41 | suppressed |
| Sotalol | Sotalol Hcl | 41 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 40 | suppressed |
| Fenofibrate | Fenofibrate | 40 | suppressed |
| Baclofen | Baclofen | 39 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 39 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 38 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 37 | 23 |
| Glipizide Er | Glipizide | 37 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 36 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 36 | suppressed |
| Topiramate | Topiramate | 36 | suppressed |
| Chlorthalidone | Chlorthalidone | 35 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 35 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 35 | suppressed |
| Ranolazine Er | Ranolazine | 33 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 33 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 32 | 12 |
| Estradiol | Estradiol | 31 | suppressed |
| Nystatin | Nystatin | 31 | suppressed |
| Brilinta | Ticagrelor | 30 | suppressed |
| Trulicity | Dulaglutide | 30 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 29 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 29 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 28 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 16 |
| Linzess | Linaclotide | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 27 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Humalog | Insulin Lispro | 26 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 26 | suppressed |
| Movantik | Naloxegol Oxalate | 26 | suppressed |
| Ssd | Silver Sulfadiazine | 26 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 26 | 15 |
| Nitroglycerin | Nitroglycerin | 25 | 17 |
| Rexulti | Brexpiprazole | 25 | suppressed |
| Admelog | Insulin Lispro | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Cephalexin | Cephalexin | 21 | 18 |
| Colchicine | Colchicine | 21 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | 14 |
| Paxlovid | Nirmatrelvir/Ritonavir | 21 | 21 |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Bumetanide | Bumetanide | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 20 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 20 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Verapamil Er | Verapamil Hcl | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 19 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 17 | suppressed |
| Cartia Xt | Diltiazem Hcl | 17 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 17 | suppressed |
| Haloperidol | Haloperidol | 17 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Risperidone | Risperidone | 17 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 16 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | 15 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 15 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 15 | 14 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Roflumilast | Roflumilast | 15 | suppressed |
| Acetic Acid | Acetic Acid | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 14 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | 11 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 14 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 14 | 13 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 14 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 14 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 12 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 13 | suppressed |
| Pentoxifylline | Pentoxifylline | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 13 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 12 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 12 | suppressed |
| Enbrel | Etanercept | 12 | suppressed |
| Felodipine Er | Felodipine | 12 | suppressed |
| Hyoscyamine Sulfate | Hyoscyamine Sulfate | 12 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Novolog | Insulin Aspart | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 11 | suppressed |
| Elmiron | Pentosan Polysulfate Sodium | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $566.72 · 29 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, BREZTRI, Dyanavel XR, FABRAZYME, FARXIGA, Ozempic, PAXLOVID, QULIPTA, REXULTI, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, Wegovy, XIFAXAN, ZENPEP | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error